Abiraterone Acetate-Induced Life-Threatening Torsade de Pointes

Abstract

Get full access to this article

View all access options for this article.

References

Naranjo

Busto

Sellers

. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30:239-245.

Kluetz

Ning

Maher

. Abiraterone acetate in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer: U.S. Food and Drug Administration drug approval summary. Clin Cancer Res. 2013;19:6650-6656.

Tolcher

Chi

Shore

. Effect of abiraterone acetate plus prednisone on the QT interval in patients with metastatic castration-resistant prostate cancer. Cancer Chemother Pharmacol. 2012;70:305-313.

Hoffmann

Warner

. Are hERG channel inhibition and QT interval prolongation all there is in drug-induced torsadogenesis? A review of emerging trends. J Pharmacol Toxicol Methods. 2006;53:87-105.

Katchman

Koerner

Tosaka

Woosley

Ebert

. Comparative evaluation of HERG currents and QT intervals following challenge with suspected torsadogenic and nontorsadogenic drugs. J Pharmacol Exp Ther. 2006;316:1098-1106.